Analyst Price Target is $13.00
▲ +254.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MediciNova in the last 3 months. The average price target is $13.00, with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 254.22% upside from the last price of $3.67.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in MediciNova. This Buy consensus rating has held steady for over two years.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.